{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:02:11Z","timestamp":1791014531597,"version":"4.1.0"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,11,5]],"date-time":"2010-11-05T00:00:00Z","timestamp":1288915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The French African Group of Pediatric Oncology was set\u2010up to improve quality of care for children with cancer. Preliminary observations on the efficacy in Burkitt lymphoma (BL) of a cyclophosphamide monotherapy (CPM) have been published. We report the results of a multicentric prospective study combining first\u2010line CPM and a multidrug second\u2010line chemotherapy (SC) for refractory\/relapsed patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Procedure<\/jats:title><jats:p>Patients \u226418 years with Burkitt or Burkitt\u2010like lymphoma, were included in six countries (Burkina\u2010Faso, Cameroon, Ivory Coast, Madagascar, Mali, and Senegal). All patients received three weekly CPM courses (1.2\u2009g\/m<jats:sup>2<\/jats:sup> IV with intrathecal methotrexate and hydrocortisone), stage 3\/4 patients received three further courses. SC added methotrexate, vincristine, cytarabine, and prednisone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were 178 patients included (42 stage 1\/2, 134 stage 3\/4, and 2 unknown). Isolated facial localization was found in 41 patients, diffuse abdominal involvement in 120 patients including 65 with both. Nine early deaths were reported, toxicity occurred in 136\/743 courses (83 patients) and was predominantly hematological. After CPM, complete remission (CR) rate was 47% with a 33% EFS. Because of rapid progression 76\/108 eligible patients (85 primary refractory and 23 relapses) received SC resulting in 35.7% CR but a 21% toxic death rate. The OS of the whole strategy was 50.5% and correlated to stage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A prospective multicentric study on BL was feasible in very low\u2010income countries. CPM can be recommended in stage 1\u20132 because of optimal cost\/benefit ratio. However, more intensive strategies, still adapted to socio\u2010economic conditions, are required for advanced stages 3 and 4. Pediatr Blood Cancer. 2010;56:70\u201376. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pbc.22746","type":"journal-article","created":{"date-parts":[[2010,11,7]],"date-time":"2010-11-07T13:42:04Z","timestamp":1289137324000},"page":"70-76","source":"Crossref","is-referenced-by-count":68,"title":["Cyclophosphamide monotherapy in children with Burkitt lymphoma: A study from the French\u2013African Pediatric Oncology Group (GFAOP)"],"prefix":"10.1002","volume":"56","author":[{"given":"Fousseyni","family":"Traor\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Coze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Jacques","family":"Atteby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Doumbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noeline","family":"Ravelomanana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diarra","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Patte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Anne","family":"Raquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Raphael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Lemerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.18004619704"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910420408"},{"key":"e_1_2_6_4_2","first-page":"158","volume-title":"Cancers de l'enfant","author":"Patte C","year":"2008"},{"key":"e_1_2_6_5_2","first-page":"499","article-title":"Le virus d'Epstein Barr et le lymphome de Burkitt","volume":"59","author":"Joab I","year":"1999","journal-title":"Med Trop"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.05.005"},{"key":"e_1_2_6_7_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pbc.20148","article-title":"Cancer incidence among children in France, 1990\u20131999","volume":"43","author":"Desandes E","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20010601)92:5<622::AID-IJC1256>3.0.CO;2-K"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.11.3370"},{"key":"e_1_2_6_10_2","first-page":"3294","article-title":"Improved treatment results in children B\u2010cells neoplasms with tailored intensification of therapy: A report of Berlin\u2010Francfurt\u2010Munster Group trial, NHL\u2010BFM 90","volume":"94","author":"Reiter A","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_11_2","first-page":"192","article-title":"Peut\u2010on traiter les cancers des enfants en Afrique. L'action du Groupe Franco\u2010Africain d'Oncologie P\u00e9diatrique","volume":"6","author":"Lemerle J","year":"2003","journal-title":"MT P\u00e9diatrie"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21452"},{"key":"e_1_2_6_13_2","first-page":"401","article-title":"Intravenous high frequency cyclophosphamide plus intrathecal methotrexate for endemic Burkitt lymphoma\u2010interim results","volume":"43","author":"Hesseling P","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_6_14_2","first-page":"332","article-title":"Classification, staging and end results of treatment of childhood non Hodgkin's lymphomas: Dissimilarities from lymphomas in adults","volume":"7","author":"Murphy SB","year":"1980","journal-title":"Semin Oncol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196504)18:4<399::AID-CNCR2820180402>3.0.CO;2-G"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10190"},{"key":"e_1_2_6_18_2","first-page":"412","article-title":"High frequency intraveinous cyclophosphamide plus intrathecal methotrexate in endemic Burkitt lymphoma. Analysis of multicentre trial in Malawi, Cameroon and Ghana","volume":"45","author":"Hesseling P","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_6_19_2","first-page":"381","article-title":"Oral cyclophosphamide and intrathecal methotrexate in 140 children with Burkitt lymphoma","volume":"47","author":"Hesseling P","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1179\/146532805X58120"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21689"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2004.01348.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880019509029569"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcped.2005.04.051"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70194-3"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(200003)34:3<206::AID-MPO8>3.0.CO;2-8"},{"key":"e_1_2_6_27_2","first-page":"2005","article-title":"The 2000 Burkitt lymphoma trial in Malawi","volume":"44","author":"Hesseling P","journal-title":"Pediatr Blood Cancer"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.trstmh.2008.02.009"},{"key":"e_1_2_6_29_2","first-page":"950","article-title":"The evolving management of Burkitt lymphoma at Red cross children's hospital","volume":"96","author":"Davidson A","year":"2006","journal-title":"S Afr Med J"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-911X(200002)34:2<143::AID-MPO15>3.0.CO;2-1"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22746","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.22746","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.22746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T08:33:15Z","timestamp":1696926795000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.22746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,5]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1002\/pbc.22746"],"URL":"https:\/\/doi.org\/10.1002\/pbc.22746","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,5]]}}}